Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Betamethasone Recombinant Mouse Monoclonal Antibody (2D5)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Betamethasone Antibody (MA566616) in SDS-PAGE
SDS-PAGE characterization of Betamethasone under reducing conditions. Lane M: Protein marker (kDa); Lane BET: Purified Betamethasone Recombinant Monoclonal (Product # MA566616). Betamethasone showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-371.
产品信息
MA566616
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
2D5
抗原
Conjugate of BET hapten and KLH.
偶联物
形式
Liquid
浓度
10 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Betamethasone is a potent systemic corticosteroid used primarily to alleviate inflammation in various conditions, including allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders. It is often administered in nano-based drug delivery systems to enhance drug release and permeability, reduce dosage, and minimize toxicity. Betamethasone's effectiveness in treating chronic inflammatory skin disorders such as psoriasis and atopic dermatitis is well-documented, with ongoing research focused on improving its delivery and efficacy. The biosimilar market for betamethasone is evolving, with strategies aimed at increasing adoption and addressing safety concerns related to switching from reference biologics to biosimilars. Betamethasone has demonstrated decreased risks for respiratory distress syndrome, intraventricular hemorrhage, and neonatal infections compared to dexamethasone, highlighting its therapeutic advantages.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
